implementation of HIPEC with the CO2 PRS, probably due to a better drug distribution in the peritoneal cavity. This is of critical importance given that pattern of recurrence as carcinomatosis is undoubtedly associated with unfavourable outcome.

EPV227/#79

OVARIAN CANCER INCIDENCE AFTER BILATERAL SALPINGO-OOPHORECTOMY IN WOMEN WITH HISTOLOGICAL PROVEN ENDOMETRIOSIS OR ADENOMYOSIS

¹M Hermens*, ²A Van Altena, ³J Bulten, ¹H Van Vliet, ⁴A Siebers, ¹R Bekkers. ¹Catharina Hospital, Obstetrics and Gynaecology, Eindhoven, Netherlands; ²Radboudumc, Obstetrics and Gynaecology, Nijmegen, Netherlands; ³Radboudumc, Pathology, Nijmegen, Netherlands; ⁴PALGA, Pathology, Houten, Netherlands

10.1136/ijgc-2021-IGCS.298

Objectives Endometriosis is associated with an increased ovarian cancer incidence. Surgical treatment of endometriosis might reduce this risk. Therefore, we assessed the ovarian cancer incidence in women with endometriosis after bilateral salpingo-oophorectomy (BSO).

Methods All women with histological proven endometriosis between 1990 and 2015 in the Netherlands were identified. Women with a BSO without ovarian cancer at time of surgery were selected as cases (n=14,410). We selected two control cohorts; 1) women with histological proven endometriosis without BSO or with ovarian cancer at time of BSO (n=115,323), and 2) women with a benign dermal nevus (n=132,654). Histological diagnoses of ovarian or extra-ovarian cancers were retrieved. Incidence rate ratios (IRR) were estimated for (extra) ovarian cancer.

Results We identified 13 (0.09%) extra-ovarian cancers in the BSO cohort and 2,036 (1.8%) and 471 (0.4%) ovarian cancers in the endometriosis and nevus cohort, respectively. We found an age-adjusted IRR of 0.02 (95%CI 0.01–0.04) when the BSO cohort was compared with the endometriosis cohort and an age-adjusted IRR of 0.20 (95%CI 0.11–0.37) when comparing the BSO to the nevus cohort (table 1). Median age at cancer diagnosis was 61 (IQR 56–74) in the BSO cohort, 55 (IQR 48–63) in the endometriosis cohort and 58 years (IQR 51–65) in the nevus cohort (both p<0.05).

Conclusions We found a significantly reduced (extra-)ovarian cancer incidence in women with endometriosis and a

Abstract EPV227/#79 Table 1 Estimated incident rates per 100,000 person-years, crude incidence rate ratios, and age-adjusted incidence rate ratios of ovarian cancer in women with endometriosis with BSO compared to 1) women with endometriosis without BSO (or BSO at time of ovarian cancer) and 2) women with a benign dermal nevus

	Incidence rate per 100,000 person-years (95% CI)	Crude incidence rate ratios (95% CI)	Age-adjusted incidence rate ratios (95% CI)
BSO	6.47 (3.75–11.14)	-	-
Endometriosis without BSO	118.40 (113.33–123.57)	0.05 (0.03–0.09)	0.02 (0.01–0.04)
Nevus	23.21 (21.20–25.40)	0.28 (0.15–0.48)	0.20 (0.11–0.37)

Data are in numbers, percentages, or incidence rate ratios. CI, confidence interval. BSO, bilateral salpingo-oophorectomy

BSO when compared to both controls with endometriosis without BSO, and controls without histological proven endometriosis.

EPV228/#80

INCREASED INCIDENCE OF OVARIAN CANCER IN BOTH ENDOMETRIOSIS AND ADENOMYOSIS

¹M Hermens*, ²A Van Altena, ³J Bulten, ¹H Van Vliet, ⁴A Siebers, ¹R Bekkers. ¹Catharina Hospital, Obstetrics and Gynaecology, Eindhoven, Netherlands; ²Radboudumc, Obstetrics and Gynaecology, Nijmegen, Netherlands; ³Radboudumc, Pathology, Nijmegen, Netherlands; ⁴PALGA, Pathology, Houten, Netherlands

10.1136/ijgc-2021-IGCS.299

Objectives Recently we conducted a study in which we found an increased association of ovarian cancer in women with endometriosis. Analyses showed that the cohort included both women with endometriosis externa and adenomyosis. Therefore, in the present study we assessed the association between endometriosis and/or adenomyosis and ovarian cancer.

Methods We identified all women with histological proven endometriosis (51,544 women) and/or adenomyosis (85,015 women) from the Dutch pathology database (1990–2015) and matched them with women with a benign dermal nevus (132,654 women). Histology results for ovarian cancer were retrieved. We estimated crude and age-adjusted incidence rate ratios (IRR) for ovarian cancer.

Results We found 1,017 (2.0%), 1,284 (1.5%) and 471 (0.4%) ovarian cancer cases in the endometriosis, adenomyosis and nevus cohort, respectively. The age-adjusted IRRs were 19.75 (95%CI 16.70–23.35) in the endometriosis cohort and 5.93 (95%CI 4.91–7.16) in the adenomyosis cohort (table 1). The highest IRRs were found for endometrioid and clear cell ovarian cancer subtypes (table 1). Excluding the first year of follow-up did not result in a significant IRR for ovarian cancer overall but resulted in a statistically significant IRRs for clear cell and endometrioid ovarian cancer (table 1).

Conclusions We found an increased ovarian cancer incidence in both histological proven endometriosis and adenomyosis. This increased incidence was largest for endometriosis. Excluding the first year of follow-up resulted in an increased incidence for endometrioid ovarian cancer in both cohorts and clear cell ovarian cancer in the endometriosis cohort.

Abstract EPV228/#80 Table 1 Observed number of ovarian cancers, estimated incidence rate per 100,000 person-years, crude incidence rate ratios and age-adjusted incidence. Rate ratios of ovarian cancers of women with endometriosis or adenomyosis compared with a benign dermal nevus, per ovarian cancer subtype and overall

	ON	IR per 100,000 person-years (95% CI)	Crude IRR (95% CI)	Age-adjusted IRR (95% CI)	ON	IR per 100,000 person-years (95% CI)	Crude IRR (95% CI)	Age-adjusted IRR (95% CI)
Clear cell								
Endometriosis	259	38.76 (34.31–43.78)	23.14 (16.14–34.13)	91.87 (59.33–141.66)	38	5.69 (4.14–7.82)	3.39 (2.08–5.56)	3.92 (2.19–7.01)
Adenomyosis	155	12.39 (10.54–14.49)	7.36 (5.05–11.08)	12.40 (7.99–19.48)	23	3.33 (2.22–5.23)	1.99 (1.05–3.81)	1.23 (0.65–2.40)
Nevus	34	1.67 (1.20–2.34)	ref	ref	32	1.85 (1.20–2.84)	ref	ref
Endometrioid								
Endometriosis	344	51.43 (46.32–57.22)	21.77 (16.06–30.09)	104.08 (72.89–148.41)	29	4.34 (3.02–6.29)	2.10 (1.26–3.45)	2.39 (1.28–4.45)
Adenomyosis	302	24.94 (21.47–28.93)	10.16 (7.48–14.08)	19.99 (13.93–28.69)	50	3.98 (3.02–5.25)	1.92 (1.25–2.97)	2.51 (1.29–4.90)
Nevus	42	2.37 (1.76–3.40)	ref	ref	41	2.02 (1.46–2.79)	ref	ref
Serous								
Endometriosis	225	35.17 (30.95–39.89)	2.58 (2.10–3.08)	8.20 (6.97–10.78)	58	8.46 (6.71–11.23)	0.85 (0.48–0.87)	0.75 (0.41–1.22)
Adenomyosis	218	41.23 (37.83–44.82)	3.02 (2.51–3.51)	4.07 (3.09–5.36)	140	11.98 (10.10–13.92)	0.89 (0.73–1.10)	1.03 (0.45–2.31)
Nevus	277	13.65 (12.13–15.35)	ref	ref	208	13.21 (11.72–14.88)	ref	ref
Mucinous								
Endometriosis	93	14.67 (12.03–17.88)	6.33 (4.43–9.17)	10.21 (5.94–17.34)	9	1.33 (0.70–2.50)	0.03 (0.20–1.43)	0.49 (0.18–1.34)
Adenomyosis	159	12.59 (10.33–14.78)	5.48 (3.95–7.74)	5.94 (2.71–11.74)	24	3.91 (2.20–6.98)	0.97 (0.51–1.85)	0.44 (0.21–0.91)
Nevus	47	2.32 (1.74–3.03)	ref	ref	39	1.92 (1.40–2.60)	ref	ref
Adenocarcinoma NOS								
Endometriosis	81	12.12 (9.75–15.07)	3.78 (2.69–5.33)	12.84 (7.80–21.16)	16	2.39 (1.47–3.91)	0.82 (0.44–1.45)	0.86 (0.42–1.76)
Adenomyosis	150	11.94 (10.17–13.93)	3.73 (2.71–5.07)	5.22 (3.94–6.95)	44	3.50 (2.44–5.17)	1.20 (0.80–1.81)	1.91 (1.08–3.38)
Nevus	65	3.20 (2.51–4.08)	ref	ref	57	2.81 (2.17–3.66)	ref	ref
All ovarian cancers								
Endometriosis	1,017	152.19 (140.12–165.04)	6.56 (5.87–7.33)	19.75 (16.70–23.35)	130	22.40 (19.24–26.04)	1.03 (0.85–1.24)	1.01 (0.75–1.35)
Adenomyosis	1,284	12.59 (10.75–14.78)	4.40 (3.84–5.09)	5.93 (4.91–7.16)	390	23.08 (20.75–25.60)	1.06 (0.91–1.23)	1.17 (0.94–1.46)
Nevus	471	23.21 (21.20–25.40)	ref	ref	439	21.69 (19.70–23.75)	ref	ref

Data are in numbers, percentages (%) or incidence rate ratios.

ON=observed number, IR=Incidence Rate, IRR=Incidence Rate Ratio, NOS=Not otherwise specified, CI=confidence interval.

Abbreviations: ON=observed number, IR=Incidence Rate, IRR=Incidence Rate Ratio, NOS=Not otherwise specified, CI=confidence interval.